Bronchopulmonary dysplasia (BPD) is the most prevalent chronic lung disease in infants and presents as a consequence of preterm birth. Due to the lack of effective preventive and treatment strategies, BPD currently represents a major therapeutic challenge that requires continued research efforts at the basic, translational, and clinical levels. However, not all very low birth weight premature babies develop BPD, which suggests that in addition to known gestational age and intrauterine and extrauterine risk factors, other unknown factors must be involved in this disease’s development. One of the main goals in BPD research is the early prediction of very low birth weight infants who are at risk of developing BPD in order to initiate the adequate preventive strategies. Other benefits of determining the risk of BPD include providing prognostic information and stratifying infants for clinical trial enrollment. In this article, we describe new opportunities to address BPD’s complex pathophysiology by identifying prognostic biomarkers and develop novel, complex in vitro human lung models in order to develop effective therapies. These therapies for protecting the immature lung from injury can be developed by taking advantage of recent scientific progress in -omics, 3D organoids, and regenerative medicine.

Additional Metadata
Persistent URL,
Journal Pediatric Research: international journal of human developmental biology
Álvarez-Fuente, M. (María), Moreno, L. (Laura), Mitchell, J.A. (Jane A.), Reiss, I.K.M, Lopez, P. (Paloma), Elorza, D. (Dolores), … del Cerro, M.J. (Maria Jesús). (2018). Preventing bronchopulmonary dysplasia: new tools for an old challenge. Pediatric Research: international journal of human developmental biology. doi:10.1038/s41390-018-0228-0